Endo Pharmaceuticals Holdings
The 10-second takeaway
For the quarter ended March 31 (Q1), Endo Pharmaceuticals Holdings missed slightly on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue improved significantly and GAAP earnings per share dropped to a loss.
Margins contracted across the board.
Endo Pharmaceuticals Holdings recorded revenue of $690.6 million. The 20 analysts polled by S&P Capital IQ expected to see revenue of $701.3 million on the same basis. GAAP reported sales were 23% higher than the prior-year quarter's $560.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.87. The 23 earnings estimates compiled by S&P Capital IQ averaged $0.87 per share. GAAP EPS were -$0.75 for Q1 compared to $0.46 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 47.2%, 1,150 basis points worse than the prior-year quarter. Operating margin was -2.6%, 2,530 basis points worse than the prior-year quarter. Net margin was -12.6%, 2,260 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $789.8 million. On the bottom line, the average EPS estimate is $1.25.
Next year's average estimate for revenue is $3.22 billion. The average EPS estimate is $5.11.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 421 members out of 441 rating the stock outperform, and 20 members rating it underperform. Among 136 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 133 give Endo Pharmaceuticals Holdings a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Endo Pharmaceuticals Holdings is outperform, with an average price target of $44.70.
The drug and healthcare investing landscape is littered with also-rans and a few major winners. Is Endo Pharmaceuticals Holdings the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add Endo Pharmaceuticals Holdings to My Watchlist.